ARCHIVES

FDA Hears More Criticism On Cancer Drug Endpoints; Joint Conferences On Criteria Recommended

This article is from The Cancer Letter archive.

Vol. 15 No. 30 | July 28, 1989

Download PDF Visit The Full Archive

Related Articles

Survival After Liver Transplant Called Excellent In Study

November 28, 2003

AHCPR Invites Ideas for Outcomes Research

June 7, 1996

In Brief: Olden Chosen To Head NIEHS; Cancer Panel To Discuss Cancer and Poverty On July 9

June 28, 1991

Pryor Bill Embodies Drug Company Fears

July 8, 1994

ODAC Recommendation for Pertuzumab Signals FDA’s Resolve In Granting Accelerated Approvals

September 20, 2013

MIT’s Sharp To Head Biology Dept.; Hynes To Head Cancer Center

April 12, 1991